Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Spondylitis, Ankylosing 1Psoriasis 1Lymphoma, Follicular 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 37Zoledronic Acid 34Letrozole 34Sodium Chloride 33Carboplatin 33Bupivacaine 31Bevacizumab 31Docetaxel 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Gemcitabine 22Oxaliplatin 21Morphine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × secukinumab × Clear all
NCT06833112 2025-02-18

Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

The Affiliated Hospital Of Guizhou Medical University

Phase 4 Not yet recruiting
10 enrolled

Spondylitis, Ankylosing

NCT04571567 2022-04-11

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

Icahn School of Medicine at Mount Sinai

Phase 4 Completed
20 enrolled
Lymphoid

Lymphoma, Follicular, Psoriasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡